89bio to Participate in Upcoming Investor Conferences

Rhea-AI Summary

89bio, a clinical-stage biopharmaceutical company focused on liver and cardio-metabolic diseases, announced its participation in upcoming investor conferences in August 2021. The events include the BTIG Virtual Biotechnology Conference on August 9, 2021, featuring a fireside chat and one-on-one meetings, and the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021. The company is developing BIO89-100, an innovative therapy for nonalcoholic steatohepatitis and severe hypertriglyceridemia. For more information, investors may contact Ryan Martins, CFO.

SAN FRANCISCO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will participate in the following upcoming investor conferences in August:

• BTIG Virtual Biotechnology Conference 2021
  Format: Fireside chat and one-on-one investor meetings
  Date: Monday, August 9, 2021
  Presentation Time: 3:30 p.m. EDT

• Canaccord Genuity 41st Annual Growth Conference
  Format: One-on-one investor meetings
  Date: Wednesday, August 11, 2021

BTIG-hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.

About 89bio
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com

Media Contact:
Peter Duckler
773-343-3069
pduckler@w2ogroup.com

FAQ

What is the date of the BTIG Virtual Biotechnology Conference for 89bio?

The BTIG Virtual Biotechnology Conference is scheduled for August 9, 2021.

What is the focus of 89bio, the company represented by stock symbol ETNB?

89bio focuses on developing therapies for liver and cardio-metabolic diseases.

When will 89bio participate in the Canaccord Genuity Growth Conference?

89bio will participate in the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021.

What is BIO89-100 developed by 89bio used for?

BIO89-100 is developed for treating nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia.

How can investors contact 89bio regarding inquiries?

Investors can contact Ryan Martins, CFO of 89bio, at investors@89bio.com.